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With the scientific and technological advances achieved in the last decades in the 
health field, in particular those related to diagnoses and treatments, the relevance and 
essentiality of the use of medicines for the treatment, control, and prevention of diseases 
tended to grow. In a world where the capitalistic organization prevails in the production 
and distribution of health products, and where the human needs do not fundamentally 
govern these processes of production and consumption of goods and services, many 
distortions and irrationalities appear in the patterns of drug use and access, as well as in 
health services in general.
It is no coincidence that the issue of access to medicines has been object of discussions 
in various forums of Global Health. Recent episodes, such as the launch of new antiviral 
medicines to treat hepatitis C or new oncologic products, all at prices considered inaccessible 
even to the health systems of high-income countries, straighten the problem of relative prices 
and costs of the current system of research and development, having the intellectual property 
as a barrier to access3. The subject raised such interest that led the Secretary-General of the 
United Nations to establish a high-level panel to discuss the problem, making it clear that this 
issue could no longer be restricted only to the World Health Organization, but extrapolated 
for political discussion at the highest level16. Additionally, the issue of access to medicines 
today is no longer restricted as a problem of poor countries or populations, but is a matter 
of global importance.
In this context, it is fundamental to define social policies by the needs of the population, 
especially the most vulnerable and socially disadvantaged segments, and to bring fairness 
and rationality in the access to health care and treatment. The project of conducting a 
national survey of medicines is part of the perspective of evaluation and monitoring of 
performance against the goals that guided the policies of health and pharmaceutical 
assistance developed in Brazil. The Pesquisa Nacional sobre Acesso, Utilização e Promoção 
do Uso Racional de Medicamentos no Brasil (PNAUM – National Survey on Access, Use and 
Promotion of Rational Use of Medicines in Brazil) constitutes a significant milestone in the 
composition of nationwide surveys that have been carried out in Brazil, as well as a historical 
record that allows the monitoring of the effect of changes caused by the economic austerity 
policies that lie on the horizon. 
The studies presented and discussed in this thematic issue of the RSP, based on the PNAUM 
(Household Survey Section), a population-based cross-sectional study that collected data 
between September 2013 and February 2014, undoubtedly, contributes decisively to the best 
knowledge of the public policy of the pharmaceutical sector in Brazil, the changes promoted 
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in the public and private demands and, above all, the initiatives that aim to increase the 
access of our populations to essential medicines.
Gadelha et al.8, when contextualizing the construction process of the PNAUM, also feature 
elements of public policy related to Science, Technology, and Innovation in Health that 
had been developed and implemented in Brazil at the time when this national survey was 
conducted. Opening the collection of articles, generated in the context of this research, the 
authors present conceptual aspects and prospects of development and consolidation of 
strategies for pharmaceutical policies by the Ministry of Health.
Analyzing a set of relevant topics in the context of appropriate pharmaceutical care and 
rational use of medicines, the articles in this supplement provide the opportunity to enjoy 
various aspects and results of pharmaceutical care policies, such as the expansion of the list 
of medicines available in the public health service network, the Popular Pharmacy Program, 
and the provision of free medication to specific diseases.
Among the articles presented, and to allow better contextualization of the methodology, 
Mengue et al.10 describe in detail the methodological aspects that guided the household 
survey of PNAUM, including the design of the study, the sampling process, the instruments 
for data collection, and the implementation in the field. Producing a sample that allows 
inferences to the urban areas and macro-regions of the Country, the survey collected data 
from 41,433 individuals in more than 20,000 households, being the first major national 
survey on access and use of medicines. The authors highlight the relevance of their results 
as a baseline for future evaluation studies on the impacts of government policies and actions 
in the fields of access and use of medicines, allowing the monitoring of the trend of these 
events among regions and social groups. The future utility of this research is another element 
valuable to consider. 
Some of the articles of this supplement focus on the characterization of the general profile 
of drug use, whether for the whole of the population or for specific demographic segments. 
Bertoldi et al.4 analyze the global prevalence of medicine, showing the high percentage of 
Brazilians (50.7%) that use medicines and confirming that medicines for acute conditions are 
more consumed (33.7%) in comparison with the ones intended for chronic diseases (24.3%). 
They also noted that the usage patterns differ among age groups and regions of the Country. 
The article focuses on the use of medicines by children under 12 years of age, da Silva Dal 
Pizzol et al.6 reviewed the data of 7,528 children. The authors noted that 31% of them used 
some medication and that most of it was used for acute health problems (27.1%), and 5.6% 
for chronic diseases. The study identified the significant regional variability and the types 
of medicines most often used by children. 
Other age group that deserved particular analysis in this supplement was that of the older 
adults, which constitute, in a scenario of accelerated population aging and high prevalence of 
chronic diseases, the segment with the highest rates of medicine consumption. Considering 
only the medicines used for eight chronic diseases surveyed by the PNAUM, the study by 
Ramos et al.13 on polypharmacy in older adults identified that 18% of older people use at least 
five medications. The researchers also analyzed the diversity of this percentage among regions, 
among individuals who own or not private health plan and according to the presence of obesity. 
Given the relevance of the chronic diseases in the Brazilian morbidity and mortality profile, 
the supplement includes three articles that address features of medicine consumption 
intended for all of these diseases or specifically for one of them, hypertension. Oliveira et al.12, 
evaluating the access to medicines for the treatment of chronic non-communicable diseases, 
they observed that 94.3% of all Brazilians with one of the chronic diseases researched by 
PNAUM, who had medication prescription for the control of the disease, had access and used 
the medication prescribed. It should be stressed that such access was total, i.e., to all the 
medication prescribed. Only 2.6% of individuals had not taken the medicines they needed in 
the past 30 days. The authors believe that national policies of medicines and pharmaceutical 
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assistance implemented in Brazil since 1999 is reaching the goal of expanding access and 
reducing inequalities. 
Tavares et al.14 analyzed the free access to medicines for chronic diseases and reported 
that 47.5% of Brazilians with these diseases obtained all the medicines they needed free of 
charge. The percentage of free access was higher among individuals of low socioeconomic 
status, but with differences regarding geographic regions and classes of medicines. The 
authors indicate the reduction of socioeconomic inequalities of access with the provision 
of free medicines. 
Studying the access to medicines for hypertension, Mengue et al. identified that of all the 
hypertensive people who knew their condition and who had received a prescription for 
treatment, 94.6% were using medication, being the total access obtained by 97.9% of them. 
The authors relate the number of medicines used by hypertension people and the types of 
medication most used by them. The article indicates that 72.0% obtained the medicines in 
the Brazilian Unified Health System (SUS) or by the Popular Pharmacy Program, and that 
only 25.7% of hypertensive Brazilians paid for the medication. 
Research on catastrophic health expenditure have been developed around the world and the 
study of this supplement that focused on this theme, conducted by Luiza et al.9, detected 
that catastrophic health expenditure occurred in 5.3% of Brazilian households and medicines 
were one of the items mentioned in 3.2%. Catastrophic expenditure was considered when 
the individual stopped buying something to pay for health expenses. The percentage of 
catastrophic household expenditure proved to be inferior to those of other countries, 
as verified in prior studies developed in various countries and in Brazil2,17. The authors9 
conclude that Brazilian policies appear to be protecting the families from these expenses. 
The provision of generic medication was one of the policies developed in the Country to 
increase the access of the population to medicines. Bertoldi et al.4, in their study, detected 
that 45.5% of the medicines used by the Brazilian population are generic, as well as 37.3% 
of those provided by SUS. The authors analyze the prevalence of the use of generics, 
stratifying by economic classes and other variables including sex, age, schooling, and 
region of the Country. 
To evaluate the rational use of medicines, the practice of self-medication and adherence of 
patients to the prescriptions were also contemplated in this supplement. Self-medication 
was the object of study of Arrais et al.1, who found a higher prevalence of this practice in the 
Northeast region and in the female population, with painkillers and muscle relaxers being 
the predominant categories. The findings confirm that self-medication is common practice 
in Brazil and the authors warn of the possible risks associated with it. 
Tavares et al.14, evaluating the factors associated with low adhesion to the treatment of 
chronic diseases, found 30.8% of low adhesion and verified that the problem is more prevalent 
in the Northeast and Midwest regions of the Country. The authors indicate the actions 
required to improve the levels of adhesion. 
Another topic covered in this supplement, considering the high frequency of use and relevance 
in sexual and reproductive health policies, was the access to contraceptives. Farias et al.7, 
addressing the use and access to oral and injectable contraceptives, reported that 28.2% of 
Brazilian women between 15 and 49 years use oral and 4.5% use injectable contraception. 
Most of them paid for the contraceptive, buying them in commercial pharmacies. 
All the articles published in this supplement provides a comprehensive overview of multiple 
significant aspects on access and use of medicines in the context lived by the Brazilian 
population. The results show the importance of maintenance and expansion of health and 
pharmaceutical policies directed to the promotion of equity in health care and access to 
the rational use of medicines.
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